Finally, the immunotherapeutic effect of HOXC13 in breast cancer was explored, and results showed that the group with higher expressed HOXC13 held higher anti-PD1/PDL1 response rates in four independent cohorts (Figure 9J). The gene discussed is HOXC13; the disease is breast carcinoma.